Safety

News

FDA points to liver injury with Amgen's Tavneos

The FDA has raised the pressure on Amgen to withdraw vasculitis drug Tavneos from the market with a report linking serious side effects to the drug.

News

BioMarin halts Voxzogo trials due to safety signal

BioMarin has suspended dosing in phase 2 trials of its achondroplasia therapy Voxzogo aimed at broadening the drug's label.

News

Safety concerns prompt Ipsen to pull Tazverik from market

Ipsen is voluntarily withdrawing its EZH2 inhibitor Tazverik from sale after a clinical trial suggested a link with secondary blood cancers.

News

After phase 3 clean sweep, Roche plans oral BTK filing in MS

Roche is preparing to file for its oral multiple sclerosis drug fenebrutinib after a third phase 3 win, but could liver toxicity be a stumbling block?

R&D

Organoid neurotoxicity testing gains momentum

Organoid-based approaches may become an integral part of neurological safety testing, offering a clearer view of risk.

News

Man with measuring tape around his torso

GLP-1 drugs linked to pancreatitis, gallbladder problems

Users of weight-loss therapies based on GLP-1 agonists have been warned to be aware of a rare complication, pancreatitis, that can be severe.

FDA points to liver injury with Amgen's Tavneos

BioMarin halts Voxzogo trials due to safety signal

Safety concerns prompt Ipsen to pull Tazverik from market

After phase 3 clean sweep, Roche plans oral BTK filing in MS

Organoid neurotoxicity testing gains momentum

GLP-1 drugs linked to pancreatitis, gallbladder problems

Lundbeck preps for key bexicaserin data around year-end

Discover a new era of healthcare panel engagement: Grounded ...

Safety

Editor's Picks